AAAAAA

   
Results: 1-9 |
Results: 9
Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection
Authors: van der Valk, M Gisolf, EH Reiss, P Wit, FWNM Japour, A Weverling, GJ Danner, SA
Citation: M. Van Der Valk et al., Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection, AIDS, 15(7), 2001, pp. 847-855
The ADAM study continued: maintenance therapy after 50 weeks of induction therapy
Authors: Reijers, MHE Weverling, GJ Jurriaans, S Roos, MTL Wit, FWNM Weigel, HM Ten Kate, RW Mulder, JW Richter, C Ter Hofstede, HJM Sprenger, H Hoetelmans, RMW Schuitemaker, H Lange, JMA
Citation: Mhe. Reijers et al., The ADAM study continued: maintenance therapy after 50 weeks of induction therapy, AIDS, 15(1), 2001, pp. 129-131
Nevirapine plus didanosine: Once or twice daily combination?
Authors: van Heeswijk, RPG Veldkamp, AI Mulder, JW Meenhorst, PL Wit, FWNM Reiss, P Lange, JMA Kwakkelstein, MO Beijnen, JH Hoetelmans, RMW
Citation: Rpg. Van Heeswijk et al., Nevirapine plus didanosine: Once or twice daily combination?, J ACQ IMM D, 25(1), 2000, pp. 93-95
Experience with nevirapine in previously treated HIV-1-infected individuals
Authors: Wit, FWNM
Citation: Fwnm. Wit, Experience with nevirapine in previously treated HIV-1-infected individuals, ANTIVIR TH, 5(4), 2000, pp. 257-266
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals
Authors: van Heeswijk, RPG Veldkamp, AI Mulder, JW Meenhorst, PL Wit, FWNM Lange, JMA Danner, SA Foudraine, NA Kwakkelstein, MO Reiss, P Beijnen, JH Hoetelmans, RMW
Citation: Rpg. Van Heeswijk et al., The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals, AIDS, 14(8), 2000, pp. F77-F82
Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection
Authors: den Brinker, M Wit, FWNM Wertheim-van Dillen, PME Jurriaans, S Weel, J van Leeuwen, R Pakker, NG Reiss, P Danner, SA Weverling, GJ Lange, JMA
Citation: M. Den Brinker et al., Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection, AIDS, 14(18), 2000, pp. 2895-2902
T-cell progenitor function during progressive human immunodeficiency virus-1 infection and after antiretroviral therapy
Authors: Clark, DR Repping, S Pakker, NG Prins, JM Notermans, DW Wit, FWNM Reiss, P Danner, SA Coutinho, RA Lange, JMA Miedema, F
Citation: Dr. Clark et al., T-cell progenitor function during progressive human immunodeficiency virus-1 infection and after antiretroviral therapy, BLOOD, 96(1), 2000, pp. 242-249
Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy
Authors: Pakker, NG Kroon, EDMB Roos, MTL Otto, SA Hall, D Wit, FWNM Hamann, D van der Ende, ME Claessen, FAP Kauffmann, RH Koopmans, PP Kroon, FP ten Napel, CHH Sprenger, HG Weigel, HM Montaner, JSG Lange, JMA Reiss, P Schellekens, PTA Miedema, F
Citation: Ng. Pakker et al., Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy, AIDS, 13(2), 1999, pp. 203-212
Outcome and predictors of failure of highly active antiretroviral therapy:One-year follow-up of a cohort of human immunodeficiency virus type 1 infected persons
Authors: Wit, FWNM van Leeuwen, R Weverling, GJ Jurriaans, S Nauta, K Steingrover, R Schuijtemaker, J Eyssen, X Fortuin, D Weeda, M de Wolf, F Reiss, P Danner, SA Lange, JMA
Citation: Fwnm. Wit et al., Outcome and predictors of failure of highly active antiretroviral therapy:One-year follow-up of a cohort of human immunodeficiency virus type 1 infected persons, J INFEC DIS, 179(4), 1999, pp. 790-798
Risultati: 1-9 |